The COVID-19 pandemic has significantly impacted cervical cancer screening worldwide by disrupting healthcare systems and limiting access. Studies from Slovenia, Italy, Ontario, Scotland, Belgium, and the USA found cervical cancer screening rates dropped around 60% in 2020 compared to 2019, likely due to lockdowns and travel restrictions. A time series analysis in Denmark found a temporary 43% drop in cervical screening following the March 2020 lockdown, though rates quickly rebounded. However, a downward trend in screening from 2018 was unrelated to the pandemic. In England, estimates suggest COVID-19 screening delays over 6 months could result in 600-630 excess cervical cancers. Two scenarios modeling screening cycle delays found higher excess cancer rates, around 40 per 100,000, in women actually screened during disruptions compared to around 6 per 100,000 with 6-month delays, highlighting inequities. A study in Puerto Rico found cervical cancer screening decreased by 80-95% during the strictest lockdown periods in March-April and July 2020 but rebounded during reopening until rising cases again restricted healthcare. Modeling in Australia estimated a 12-month disruption to cervical cancer screening could increase diagnoses by up to 3.6% over 2020-2022, with expected worsening staging. Findings emphasize continuing screening amid disruptions to minimize burden. A U.S. study found colposcopy screening rates remained stable during COVID-19 despite longer intervals between Pap tests. Though pre-COVID to post-COVID vaccine Pap test intervals increased from 490 to 670 days, the proportion receiving guideline-colposcopies did not significantly differ. Shorter colposcopy-to-abnormal Pap test intervals, from 104 to 57 days, may have optimized screening. However, longer-term studies are needed to determine delayed screening's full impact. In summary, while cervical cancer screening significantly declined during COVID-19 restrictions, rates have largely rebounded as healthcare systems adapt. Continuing screening, especially for high-risk groups, and minimizing future disruptions remain critical to controlling cervical cancer. Careful monitoring and research on the broad, global impact of COVID-19 screening declines can help strengthen health systems and address inequities as we emerge from this public health crisis.